Dr Reddy’s to conduct phase-3 trials of Russian COVID vaccine Sputnik V in India

The Pharma company has reportedly asked permission from the Drugs Controller General of India.

One of the leading Pharma companies in India, Dr Reddy’s has asked DCGI to conduct phase-3 human clinical trials of Sputnik V in India on Friday.

According to the officials, the Russian Direct Investment Fund (RDIF) will supply 100 M doses of Sputnik to Dr Reddy’s upon the approval.According to the source, Drugs Controller General of India is currently evaluating the technical aspects of the application, and soon a decision comes on the approval.

It is known news that the Hyderabad-based pharma company has associated with RDIF to conduct clinical trials of Sputnik V and also for its distribution.The Sputnik V vaccine has combinedly developed by Gamaleya National Research Centre of Epidemiology and Microbiology and RDIF in Russia.

Reportedly, the officials are conducting the phase-3 trials of the vaccine in Russia since September 1.Coming to Indian vaccines, Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been conducting their phase 2 of human clinical trials.Of all the three, sources say, Sputnik V is said to be more effective as the clinical trials demonstrated that 100% of volunteers developed immunity in just 21 days.